Tesamorelin 10mg

Research Description

• Mechanism of Action: Tesamorelin works by binding to GHRH receptors in the anterior pituitary gland, which stimulates the synthesis and pulsatile release of endogenous growth hormone. This differs from direct GH injections, which can disrupt the body’s natural hormonal feedback loops. The peptide is modified with a trans-3-hexenoic acid group to enhance its stability and provide greater resistance to enzymatic degradation, giving it a longer half-life than native GHRH.
• Primary Indication: It is clinically used to treat HIV-associated lipodystrophy, a condition characterized by abnormal fat redistribution and accumulation of visceral adipose tissue (VAT). Clinical trials have shown that tesamorelin can lead to an approximately 15-20% reduction in VAT without significantly affecting subcutaneous fat.
• Broader Research Applications: Beyond its FDA-approved use, tesamorelin is a subject of active research in several areas:
  • Metabolic Disorders: Investigated for treating nonalcoholic fatty liver disease (NAFLD), insulin resistance, and metabolic syndrome in the general population.
  • Body Composition: Studies explore its potential to improve muscle mass and density (counteracting sarcopenia, or age-related muscle loss) and enhance lipid profiles by lowering triglycerides and total cholesterol.
  • Neurocognitive Function: Emerging research suggests potential benefits for cognitive function, neuroprotection, and supporting synaptic plasticity in healthy older adults and those with mild cognitive impairment.
  • Cardiovascular Health: Research indicates it may improve markers of cardiovascular health, such as reducing carotid intima-media thickness (cIMT) and C-reactive proteins (CRP).